除热原隧道与高压灭菌器的确认与验证难点及法规差异分析

当前行业遵循FDA、EU GMP、ICH等多项国内外法规标准，依托干热除热原、饱和蒸汽灭菌技术实现微生物与热原管控。但设备温度不均、蒸汽穿透不足、全球法规标准不统一等问题，持续引发验证偏差与合规风险。

本文解析这两类设备的验证难点、合规漏洞，结合实际案例与标准规范，梳理全生命周期验证要求并提出优化改进方案。

Depyrogenation tunnels and autoclaves lead to non‑negotiable critical control points in sterile pharmaceutical manufacturing, enforcing terminal removal of bacterial endotoxins and microbial contaminants from primary packaging components and processing equipment. With the help of dry‑heat thermodynamics, depyrogenation tunnels are able to achieve ≥3‑log endotoxin reduction per USP <85>, while autoclaves deploy saturated steam sterilization at 121 degrees C/15 psi to attain sterility assurance levels (SAL) of 10⁻⁶ under ISO 17665‑1:2019.
除热原隧道和高压灭菌器是无菌制药生产中不可妥协的关键控制点，用于对初级包装组件和工艺设备实现细菌内毒素与微生物污染物的最终去除。借助干热热力学原理，除热原隧道可按照 USP <85 > 要求实现不低于 3 个对数单位的内毒素去除；高压灭菌器采用 121 摄氏度 / 15 磅每平方英寸的饱和蒸汽灭菌，依据 ISO 17665‑1:2019 实现 10 的负 6 次方的无菌保证水平。

Regulatory mandates including FDA 21 CFR 211.113, EU GMP Annex 1 (2022), and ICH Q9 require comprehensive life cycle validation spanning design qualification (DQ) to continuous monitoring in order to mitigate pyrogenic and microbiological risks. These regulations classify depyrogenation tunnels and autoclaves as direct product‑contact systems requiring full validation under ICH Q10 Pharmaceutical Quality Systems.
包括美国 FDA 21 CFR 211.113、欧盟 GMP 附录 1（2022 版）以及 ICH Q9 在内的法规要求开展全生命周期完整验证，范围覆盖设计确认（DQ）至持续监控，以此降低热原和微生物相关风险。上述法规将除热原隧道与高压灭菌器划分为直接接触产品的系统，按照 ICH Q10 药品质量体系要求需要完成全套验证。

Depyrogenation came as a regulatory requirement following the 1970s endotoxin crisis, where pyrogenic reactions traced to insufficient vial processing catalyzed USP <85> Bacterial Endotoxins Test standards. Contemporary tunnels now integrate infrared heating zones calibrated to maintain 250 degrees C to 350 degrees C for validated dwell times, achieving FH≥45 minutes per PDA Technical Report 48 to ensure 3‑log endotoxin reduction. Crucially, Annex 1 §8.24 requires laminar airflow at 0.45 m/s ±20% within ISO Class 5 environments to prevent particle ingress during cooling.
20 世纪 70 年代发生内毒素危机之后，除热原成为一项法规强制要求。当时由于西林瓶处理工艺不足引发热原反应，直接推动了 USP <85 > 细菌内毒素检查标准的出台。现代除热原隧道配置红外加热区，经过校准可维持 250 摄氏度至 350 摄氏度的温度以及经过验证的停留时间，按照 PDA 技术报告 48 实现 FH 值不低于 45 分钟，保证 3 个对数单位的内毒素去除。至关重要的是，附录 1 第 8.24 条要求在 ISO 5 级环境中，层流风速达到 0.45 米每秒，允许正负百分之二十偏差，防止冷却阶段微粒进入。

Autoclave validation operates under distinct but equally rigorous frameworks. FDA's 2011 Process Validation Guidance: Stage 1 (Process Design) mandates steam penetration studies per ISO 17665‑1:2019 §5.3.2 for porous loads like rubber stoppers. Industrial autoclaves must show air removal efficacy through fractional vacuum cycles achieving ≤0.5% residual air volume, as non‑condensable gases insulate microbial spores from lethal heat transfer.
高压灭菌器验证遵循另一套独立但同等严格的框架。美国 FDA 2011 年工艺验证指南第一阶段（工艺设计）要求，针对胶塞这类多孔装载物，依据 ISO 17665‑1:2019 第 5.3.2 条开展蒸汽穿透研究。工业高压灭菌器必须通过分段真空循环证明空气去除效果，残余空气体积不得高于百分之零点五；因为不凝气体会阻隔微生物孢子，使其无法接触致死热量。

The 2012 New England Compounding Center tragedy, involving 64 fatalities from under‑validated autoclaves, precipitated FDA's 2013 Sterile Compounding Guidance requiring triannual requalification. Modern systems now embed thermocouples at cold spots identified via temperature mapping per ASTM E3106‑18, ensuring ≤±2.5 degrees C uniformity during sterilization holds.
2012 年新英格兰配药中心事故中，高压灭菌器验证不充分造成 64 人死亡，促使美国 FDA 在 2013 年发布无菌配药指南，要求每三年开展一次再确认。现代设备会按照 ASTM E3106‑18，通过温度分布测绘确定冷点位置并布置热电偶，保证灭菌保温阶段温度均匀性偏差不超过正负 2.5 摄氏度。

Regulatory divergence persists, however; while EU Annex 1 §8.26 demands real‑time particle monitoring during depyrogenation, 21 CFR 211.67 permits parametric release without endotoxin challenges — creating compliance asymmetries for global facilities.
但法规之间仍然存在差异：欧盟附录 1 第 8.26 条要求除热原过程实施实时微粒监控，而美国 21 CFR 211.67 允许不开展内毒素挑战性试验即实施参数放行，这给跨国工厂带来合规上的不对等。

Autoclaves, initially developed for surgical sterilization in the 19th century, evolved into industrial‑scale systems for pharmaceutical use. Steam sterilization at 121 degrees C under pressure remains the gold standard due to its sporicidal efficacy.
高压灭菌器最初于 19 世纪开发用于外科器械灭菌，之后发展为制药行业使用的工业级设备。加压条件下 121 摄氏度蒸汽灭菌凭借良好的杀孢子能力，至今仍是金标准。

However, challenges like incomplete air removal and uneven heat distribution necessitated the development of validation protocols, including steam penetration studies and biological indicator (BI) testing.
但空气去除不完全、热量分布不均等问题，推动了验证方案的发展，其中包括蒸汽穿透研究与生物指示剂（BI）测试。

Regulatory frameworks like FDA’s process validation guidance (2011) and ISO 17665 now mandate life cycle approaches encompassing design qualification (DQ), installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ).
美国 FDA 2011 年工艺验证指南、ISO 17665 等法规框架要求采用全生命周期方法，涵盖设计确认 DQ、安装确认 IQ、运行确认 OQ、性能确认 PQ。

The 2012 FDA warning letters citing inadequate autoclave validation at compounding pharmacies underscored the industry’s vulnerability to noncompliance. Similarly, depyrogenation failures linked to uneven airflows in tunnels have resulted in product recalls, emphasizing the need for robust thermal mapping. New technologies, such as continuous monitoring sensors and adaptive cycle algorithms, aim to address these gaps. However, harmonizing global standards remains challenging, particularly for advanced therapies requiring ultra‑clean environments.
2012 年 FDA 向配药药房出具警告信，指出高压灭菌器验证不足，凸显行业容易出现不合规问题。与之类似，隧道内部气流不均造成除热原失效，引发多起产品召回，说明可靠的温度分布测绘必不可少。连续监控传感器、自适应循环算法等新技术致力于解决上述缺陷。但全球标准协调依旧存在难度，对于需要超高洁净环境的先进疗法产品尤为突出。

The validation life cycle for depyrogenation tunnels and autoclaves confronts systemic vulnerabilities in four domains: thermal uniformity assurance, steam penetration verification, regulatory fragmentation, and technology harmonization. These deficiencies directly threaten product sterility and trigger regulatory sanctions.
除热原隧道和高压灭菌器的验证全生命周期，在四个方面存在系统性薄弱点：温度均匀性保障、蒸汽穿透确认、法规碎片化、技术标准协调。上述缺陷会直接威胁产品无菌状态，并招致监管处罚。

Endotoxin Survival In Thermal Cold Zones
热冷点区域的内毒素存活风险

USP <85> §3 mandates minimum 250 degrees C exposures for endotoxin destruction, but heterogeneous vial geometries create thermal gradients exceeding 15 degrees C in tunnel edge lanes. FDA's 2019 inspection of a New Jersey facility documented Form 483 Observation 5.1.3 due to unvalidated cold zones at conveyor edges, permitting endotoxin survival in 0.1% of vials.
USP <85 > 第 3 条规定，破坏内毒素至少需要 250 摄氏度的处理条件；但西林瓶外形差异，会造成隧道传送带边缘通道的温度梯度超过 15 摄氏度。FDA 2019 年对新泽西一家工厂检查，出具 483 观察项 5.1.3，原因是传送带边缘存在未经验证的冷点，造成百分之零点一的西林瓶出现内毒素残留存活。

PDA Journal (2021) attributed such failures to HEPA filter bypass allowing particulate accumulation on heating coils, disrupting laminar flow. EU Annex 1 §8.23 now requires quarterly airflow smoke studies to detect dead zones, increasing validation costs by 25% for legacy systems.
2021 年 PDA 期刊将该类失效归因为高效过滤器发生旁通，微粒在加热盘管堆积，扰乱层流状态。欧盟附录 1 第 8.23 条目前要求每季度开展气流烟雾试验，识别死区，老旧系统的验证成本因此提升百分之二十五。

Non‑Uniform Steam Penetration In Porous Loads
多孔装载物的蒸汽穿透不均匀问题

Autoclave failures predominantly stem from inadequate air removal in complex assemblies. ISO 17665‑1:2019 §7.4 specifies ≥99% air evacuation for rubber stopper sterilization, yet steam penetration studies routinely identify condensate pools in stopper cavities.
高压灭菌器故障大多来源于复杂装载物的空气去除不充分。ISO 17665‑1:2019 第 7.4 条要求胶塞灭菌时空气排出率不低于百分之九十九；但蒸汽穿透研究经常发现胶塞凹槽内部存在冷凝水积聚。

A 2023 EMA noncompliance report cited 31% of autoclave deviations linked to faulty vacuum pumps, allowing Geobacillus stearothermophilus spore survival. FDA's Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice (2004) requires thermocouple placement within product simulants to verify lethal conditions, but 2022 warning letters revealed 40% of manufacturers omitted probes from load cold spots.
2023 年 EMA 不合规报告显示，百分之三十一的高压灭菌器偏差来自真空泵故障，造成嗜热脂肪地芽孢杆菌孢子存活。美国 FDA 行业指南《无菌工艺生产的无菌药品现行药品生产质量管理规范》（2004）要求在产品模拟件内部布置热电偶确认致死条件；但 2022 年警告信数据显示，百分之四十的企业没有在装载物冷点布置探头。

Biological indicators (BIs) containing Geobacillus stearothermophilus spores fail to inactivate in such scenarios, with a 2018 JAMA study reporting a 7% BI failure rate in healthcare autoclaves. Porous materials like rubber stoppers exacerbate air entrapment, requiring fractional pre‑vacuum cycles per ISO 17665. However, improper maintenance of vacuum pumps or door gaskets can compromise air removal efficiency.
在该类情形下，含有嗜热脂肪地芽孢杆菌孢子的生物指示剂（BI）无法完成灭活；2018 年 JAMA 研究显示医疗机构高压灭菌器的生物指示剂失效率为百分之七。胶塞这类多孔材料会加剧空气截留，按照 ISO 17665 要求需要采用分段预真空循环。但真空泵或者门密封垫圈维护不当，会降低空气去除效率。

Life Cycle Validation Deficiencies Under ICH Q10
ICH Q10 框架下的全生命周期验证缺陷

Regulators increasingly enforce ICH Q10's life cycle model requiring ongoing process verification. However, FDA's 2021 citation of a Pfizer facility cited inadequate risk assessments during autoclave requalification after steam generator upgrades, violating 21 CFR 211.68 (a).
监管机构越来越严格执行 ICH Q10 全生命周期模型，要求持续工艺确认。但 FDA 2021 年对辉瑞工厂出具缺陷，指出蒸汽发生器升级之后，高压灭菌器再确认阶段风险评估不足，违反 21 CFR 211.68 (a) 条款。

Regulatory agencies increasingly enforce life cycle‑based validation per FDA’s 2011 process validation guidance, but many firms remain reliant on outdated “3Q” (IQ/OQ/PQ) protocols. A 2021 FDA warning letter criticized a vaccine manufacturer for omitting risk assessments during autoclave requalification, resulting in unreported temperature fluctuations during lyophilizer sterilization.
监管机构按照 FDA 2011 工艺验证指南推行基于全生命周期的验证，但大量企业仍然沿用老旧的 “3Q”（IQ/OQ/PQ）方案。2021 年 FDA 警告信批评一家疫苗企业，高压灭菌器再确认阶段缺少风险评估，造成冻干机灭菌过程出现未上报的温度波动。

Similarly, EU GMP Annex 1’s 2022 revision mandates stricter particle monitoring during depyrogenation tunnel operation, yet legacy systems lack integrated environmental sensors. Noncompliance often arises from fragmented documentation. Similarly, EU Annex 1 §9.43 mandates requalification following tunnel filter changes, but MHRA's 2023 audit found 60% of U.K. sites lacked change control protocols. The financial impact is severe: Recalls due to incomplete OQ documentation cost manufacturers $500 million annually per ISPE surveys.
与之类似，欧盟 GMP 附录 1 2022 修订版要求除热原隧道运行阶段执行更严格的微粒监控，但老旧设备没有集成环境传感器。文档碎片化经常引发不合规。欧盟附录 1 第 9.43 条要求隧道过滤器更换后开展再确认，但英国 MHRA 2023 年审计发现，百分之六十的英国工厂缺少变更控制规程。造成巨大经济损失：ISPE 调查显示，每年因运行确认 OQ 文档不全引发的产品召回给企业造成五亿美元损失。

Regulatory Disharmony For Advanced Systems
先进设备面临的法规不协调问题

Divergent regulatory expectations complicate validation for multinational manufacturers. While FDA emphasizes parametric release for depyrogenation tunnels under 21 CFR 211.94, EU GMP Annex 17 requires additional endotoxin challenge tests, increasing validation costs by 30%–40%.
不同监管机构的要求不一致，给跨国制药企业的验证工作带来困难。美国 FDA 依据 21 CFR 211.94 支持除热原隧道采用参数放行；而欧盟 GMP 附录 17 要求额外开展内毒素挑战性试验，使验证成本提升百分之三十至四十。

Emerging technologies like RFID‑enabled autoclave sensors or adaptive depyrogenation algorithms face ambiguous compliance pathways; ISO 17665‑1 lacks explicit guidelines for real‑time cycle adjustments, forcing firms to seek case‑by‑case approvals.
射频识别 RFID 高压灭菌器传感器、自适应除热原算法等新兴技术，合规路径尚不明确；ISO 17665‑1 没有针对实时循环调整给出明确指南，企业只能申请个案审批。

Divergent standards impede innovation adoption. While FDA 21 CFR 211.68 permits AI‑driven adaptive depyrogenation cycles, EU Annex 1 §8.4 requires fixed parameters unless revalidated. ISO 17665‑1 lacks provisions for RFID‑enabled autoclave sensors, forcing manufacturers into costly case‑by‑case submissions. PMDA's requirement for annual requalification (versus FDA's three‑year cycles) creates $1.2 million/year compliance overhead for multinationals.
标准差异阻碍新技术落地。美国 FDA 21 CFR 211.68 允许人工智能驱动的自适应除热原循环；欧盟附录 1 第 8.4 条要求参数固定，除非完成再验证。ISO 17665‑1 没有纳入 RFID 高压灭菌器传感器相关条款，企业需要承担高额成本进行个案申报。日本 PMDA 要求每年再确认，而 FDA 是三年周期，跨国企业每年因此增加一百二十万美元的合规成本。

A 2023 ISPE survey noted that 65% of respondents delayed adopting continuous monitoring systems due to conflicting FDA and EMA data integrity requirements. Furthermore, ICH’s Q12 guideline struggles to address regional disparities in revalidation criteria, with Japan’s PMDA mandating annual requalification versus FDA’s risk‑based intervals.
ISPE 2023 年调查显示，百分之六十五的受访者因为 FDA 和 EMA 的数据完整性要求相互冲突，推迟上线连续监控系统。同时 ICH Q12 指南难以解决各地区再确认标准差异，日本 PMDA 要求每年再确认，FDA 采用基于风险的周期。

This discordance impedes global supply chains, particularly for ATMPs (advanced therapy medicinal products) requiring ultra‑clean depyrogenation environments unaddressed by current USP chapters.
该类标准不一致会干扰全球供应链，尤其对于先进疗法药品 ATMP，该类产品需要超高洁净除热原环境，而现行 USP 各论尚未覆盖相关场景。

Regulatory‑Driven Imperatives For Sterilization System Validation
法规对灭菌系统验证的强制要求

Global Compliance Through Life Cycle Validation
依托全生命周期验证实现全球合规

Regulatory mandates under FDA 21 CFR 211.113 and EU GMP Annex 1 (2022) Article 8.26 establish nonnegotiable validation requirements for depyrogenation tunnels and autoclaves. These frameworks demand documented evidence of consistent 3‑log endotoxin reduction (USP <85> §3) and sterility assurance levels (SAL) of 10⁻⁶ (ISO 17665‑1:2019 §5.2).
美国 FDA 21 CFR 211.113 以及欧盟 GMP 附录 1（2022）第 8.26 条，对除热原隧道与高压灭菌器设置不可妥协的验证要求。法规框架要求提供书面证据，证明可以稳定实现 3 个对数单位内毒素去除（USP <85 > 第 3 条）以及 10 的负 6 次方无菌保证水平（ISO 17665‑1:2019 第 5.2 条）。

FDA's 2011 process validation guidance §III.B mandates a life cycle approach where manufacturers must continuously monitor critical parameters like belt speed and steam saturation. For example, EU Annex 1 §8.43 requires quarterly requalification of tunnel HEPA filters using photometer testing per ISO 14644‑3:2019, while 21 CFR 211.67 (c) compels autoclave requalification after component replacements.
FDA 2011 工艺验证指南第 III.B 部分要求采用全生命周期思路，企业必须持续监控传送带速度、蒸汽饱和度这类关键参数。举例来说，欧盟附录 1 第 8.43 条，按照 ISO 14644‑3:2019 光度计测试方法，隧道高效过滤器每季度再确认；21 CFR 211.67 (c) 要求高压灭菌器更换部件之后执行再确认。

Noncompliance triggers immediate action: In 2023, the FDA issued Warning Letter WL 320‑23‑01 to a sterile manufacturer for violating 21 CFR 211.113 when requalification records omitted temperature mapping after conveyor motor replacement.
不合规会触发即时监管处置：2023 年 FDA 向一家无菌制剂企业出具警告信 WL 320‑23‑01，企业更换传送带电机后，再确认记录缺少温度分布测绘，违反 21 CFR 211.113 条款。

Mitigating Contamination Risks Through Scientific Controls
依靠科学控制手段降低污染风险

Validation protocols directly prevent pyrogenic reactions and microbial contamination by enforcing quantifiable lethality thresholds. Depyrogenation tunnels must show endotoxin reduction via lipopolysaccharide challenges at the coldest location identified through thermal mapping per ASTM E3106‑18 §6.3. EU Annex 1 §8.24 mandates these challenges to use 10,000 EU/ml concentrations with recovery ≤5% post‑exposure.
验证方案通过执行可量化的致死阈值，直接避免热原反应与微生物污染。除热原隧道必须按照 ASTM E3106‑18 第 6.3 条，在温度分布测绘找到的最冷点位开展脂多糖挑战性试验，证明内毒素去除效果。欧盟附录 1 第 8.24 条要求挑战性试验使用每毫升一万内毒素单位，处理之后回收率不得高于百分之五。

For autoclaves, biological indicators containing Geobacillus stearothermophilus spores (ISO 11138‑3:2017 §5.4) must show ≥12‑log reduction in porous load studies. The 2012 NECC tragedy, resulting from autoclave validation gaps under 21 CFR 211.94, showed catastrophic consequences: FDA investigators confirmed Exserohilum rostratum survival due to inadequate steam penetration validation in stopper loads.
对于高压灭菌器，多孔装载物试验中，含有嗜热脂肪地芽孢杆菌孢子的生物指示剂（ISO 11138‑3:2017 第 5.4 条）必须实现不低于 12 个对数单位的灭活。2012 年 NECC 事故源于 21 CFR 211.94 框架下高压灭菌器验证缺陷，造成灾难性后果：FDA 调查确认，胶塞装载物蒸汽穿透验证不足，造成突脐蠕孢存活。

Modern protocols now require thermocouple placement within product simulants to verify lethal conditions.
现代验证方案要求在产品模拟件内部布置热电偶，确认达到致死条件。

Optimizing Resource Utilization Through Regulatory Alignment
通过法规对齐优化资源投入

Validation life cycle management reduces operational costs by preventing deviations that trigger shutdowns. PQ per ISO 17665‑1 §8.2 identifies inefficiencies like extended autoclave cycles caused by non‑condensable gases >0.5% volume (ISO 18465:2017 limit).
全生命周期验证管理可以避免偏差造成的生产停工，降低运行成本。按照 ISO 17665‑1 第 8.2 条开展的性能确认 PQ，能够识别各类低效问题，例如不凝气体体积超过百分之零点五（ISO 18465:2017 限度）造成高压灭菌器周期被拉长。

A 2022 ISPE study documented 23% energy savings after requalifying tunnel belt speeds to maintain FH≥45 minutes (USP <1228> §4.2). Conversely, EU Annex 1 §9.44 mandates annual airflow visualization studies, with noncompliance causing 18‑day production halts during EMA inspections as reported in PHSS Technical Monograph 2023.
ISPE 2022 年研究显示，重新确认隧道传送带速度保证 FH≥45 分钟（USP <1228 > 第 4.2 条）之后，可以节约百分之二十三的能耗。与之相反，欧盟附录 1 第 9.44 条要求每年开展气流可视化试验，PHSS 2023 技术专著记录，企业不合规会在 EMA 检查期间遭遇十八天的生产停工。

The MHRA's 2023 audit program revealed that facilities aligning with ICH Q10 Pharmaceutical Quality Systems reduced validation costs by 35% through integrated change control protocols.
英国 MHRA 2023 审计项目数据表明，工厂落实 ICH Q10 药品质量体系，使用一体化变更控制规程，验证成本可以降低百分之三十五。

Accelerating Technology Adoption Via Compliance Frameworks
依托合规框架加快新技术落地

Regulatory evolution enables next‑generation system integration when supported by risk‑based validation. FDA's 2023 digital twins guidance §4.1 permits AI‑driven thermal control in depyrogenation tunnels if algorithm validation includes worst‑case challenge studies per ASTM E3078‑22.
法规迭代配合基于风险的验证，为下一代设备集成创造条件。FDA 2023 数字孪生指南第 4.1 条允许除热原隧道采用人工智能温度控制，但算法验证必须按照 ASTM E3078‑22 完成最差条件挑战性研究。

For autoclaves, pulsed‑sparging cycles require steam penetration mapping per ISO 17665‑1 Annex B. However, regulatory gaps persist: ISO 17665‑1 lacks provisions for real‑time BI monitoring via RFID, forcing manufacturers to submit 510 (k) applications under 21 CFR 807.81.
高压灭菌器脉冲喷射循环，需要按照 ISO 17665‑1 附录 B 开展蒸汽穿透测绘。但仍然存在法规空白：ISO 17665‑1 没有针对 RFID 实时生物指示剂监控做出规定，企业只能按照 21 CFR 807.81 提交 510 (k) 申报。

ICH Q14 draft §3.2 proposes standardized AI validation, but harmonization with USP <1229.1> for adaptive cycles remains incomplete, delaying implementation of Bosch's LyoTunnel AI systems in EMA‑regulated facilities.
ICH Q14 草案第 3.2 条提出人工智能标准化验证，但自适应循环相关内容尚未和 USP <1229.1 > 完成协调，博世 LyoTunnel 人工智能系统在 EMA 管辖工厂的落地因此推迟。

Regulatory Codification Of Validation Protocols
验证方案的法规成文规定

Depyrogenation tunnel validation operates under a tripartite regulatory framework: Installation qualification (IQ) must verify HEPA filter integrity per ISO 14644‑3 §B.6.2 and airflow velocity ≥0.45 m/s ±20% (EU Annex 1 §8.24). Operational qualification (OQ) requires thermal mapping with ≥15 thermocouples per ASTM E3106‑18 §5.1 to confirm ±2.5 degrees C uniformity.
除热原隧道验证采用三方法规框架：安装确认 IQ 必须按照 ISO 14644‑3 附录 B.6.2 确认高效过滤器完整性，并且风速达到 0.45 米每秒，允许正负百分之二十偏差（欧盟附录 1 第 8.24 条）。运行确认 OQ 按照 ASTM E3106‑18 第 5.1 条，使用不少于 15 支热电偶开展温度分布测绘，确认温度均匀性正负 2.5 摄氏度。

Performance qualification (PQ) mandates three consecutive endotoxin challenges at minimum belt speed using E. coli O55:B5 LPS per USP <85> §3. For autoclaves, FDA 21 CFR 211.113 requires IQ to certify vacuum pump performance achieving ≤0.5 kPa residual air.
性能确认 PQ，按照 USP <85 > 第 3 条，使用大肠杆菌 O55:B5 脂多糖，在最低传送带速度下连续完成三次内毒素挑战性试验。对于高压灭菌器，FDA 21 CFR 211.113 要求安装确认 IQ 证明真空泵性能，残余空气压力不高于零点五千帕斯卡。

OQ must validate steam penetration in porous loads with thermocouples embedded in stopper matrices per ISO 17665‑1 §7.4. PQ necessitates biological indicator inactivation studies with G. stearothermophilus ATCC 7953 spores placed at cold spots identified during mapping. Japan's PMDA additionally requires moisture residue testing for lyophilizer‑associated autoclaves under JP XVIII General Rules 32, while EU Annex 1 §8.26 imposes annual requalification with airflow smoke studies.
运行确认 OQ 按照 ISO 17665‑1 第 7.4 条，将热电偶埋入胶塞本体，验证多孔装载物的蒸汽穿透效果。性能确认 PQ 需要把 ATCC 7953 嗜热脂肪地芽孢杆菌孢子生物指示剂布置在测绘识别的冷点，开展灭活研究。日本 PMDA 依据日本药典第十八版通则 32，额外要求和冻干机配套的高压灭菌器开展残留水分测试；欧盟附录 1 第 8.26 条要求每年再确认并开展气流烟雾试验。

Analysis/Recommendations
分析与建议

Current regulatory fragmentation imposes unsustainable compliance burdens, as evidenced by PMDA’s annual autoclave requalification mandate (JP XVIII General Rules 32) versus FDA’s risk‑based intervals under 21 CFR 211.113.
当前法规碎片化造成难以承受的合规负担，典型例子：日本 PMDA 依据日本药典第十八版通则 32 强制高压灭菌器每年再确认，而 FDA 21 CFR 211.113 采用基于风险的周期。

Manufacturers should advocate for ICH Q12 Annex 2 adoption to standardize change control thresholds, reducing validation costs by 30% as shown in Moderna’s 2022 mRNA facility validation. The EMA’s 2023 Compilation of Procedures §5.23 already permits reduced testing for established processes, but alignment with FDA’s 2011 process validation guidance §III.C requires formal ICH ratification.
企业应当推动采纳 ICH Q12 附录 2，统一变更控制判定阈值；莫德纳 2022 年 mRNA 工厂验证数据显示，该举措可以降低百分之三十验证成本。EMA 2023 程序汇编第 5.23 条已经允许成熟工艺减少测试，但要和 FDA 2011 工艺验证指南第 III.C 条对齐，还需要 ICH 正式批准。

Legacy standards like ISO 17665‑1:2019 lack provisions for real‑time BI monitoring via RFID sensors, forcing manufacturers into costly 510 (k) submissions per 21 CFR 807.81. Regulatory bodies must expedite revisions to ASTM E3078‑22 (digital twins) to incorporate machine learning algorithms for predictive cycle adjustments.
ISO 17665‑1:2019 这类现有标准没有纳入 RFID 传感器实时生物指示剂监控，企业只能按照 21 CFR 807.81 承担高额成本提交 510 (k) 申报。监管机构应当加快修订 ASTM E3078‑22（数字孪生），纳入用于预测性循环调整的机器学习算法。

FDA’s 2023 AI/ML Action Plan §4.2 provides a template, requiring algorithm validation with 95% confidence intervals across worst‑case scenarios. Simultaneously, autoclave manufacturers should integrate pulsed‑sparging cycles with steam quality sensors meeting ISO 18465:2017 §6.2 standards to eliminate non‑condensable gases.
FDA 2023 人工智能 / 机器学习行动计划第 4.2 条提供参考模板，算法需要在各类最差条件下完成验证，置信区间百分之九十五。同时高压灭菌器设备厂商应当配置脉冲喷射循环，搭配满足 ISO 18465:2017 第 6.2 条的蒸汽质量传感器，消除不凝气体。

EU Annex 1 §9.44’s requirement for continuous particle monitoring necessitates quality‑by‑design (QbD) approaches during tunnel procurement. Manufacturers must enforce ASTM E3106‑18 §7.3 during DQ to ensure ≥30 thermocouple ports for thermal mapping.
欧盟附录 1 第 9.44 条要求连续微粒监控，企业采购隧道阶段就要采用质量源于设计 QbD 思路。设计确认 DQ 阶段必须执行 ASTM E3106‑18 第 7.3 条，保证设备预留不少于三十个热电偶接口用于温度分布测绘。

Post‑OQ, Annex 1 §8.26 mandates statistical process control (SPC) of belt speeds with ±1% tolerance, achievable through PAT tools per the FDA’s Guidance for Industry: PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance (2004). Training programs aligned with PDA TR 1 (2023) should incorporate Annex 1 §9.8’s personnel qualification requirements, targeting zero critical observations during MHRA inspections.
运行确认 OQ 完成后，附录 1 第 8.26 条要求传送带速度执行统计过程控制 SPC，允许正负百分之一偏差，可按照 FDA 2004 年 PAT 行业指南，借助过程分析技术 PAT 工具实现。培训体系应当匹配 PDA TR 1（2023），落实附录 1 第 9.8 条人员资质要求，争取在 MHRA 检查中实现零关键缺陷。

Conclusion
结论

Depyrogenation tunnels and autoclaves demand uncompromising validation rigor to satisfy FDA 21 CFR 211.113 endotoxin removal criteria and EU Annex 1 SAL 10⁻⁶ mandates. The life cycle approach under ICH Q10 remains nonnegotiable, requiring IQ/OQ/PQ protocols that verify ±2.5 degrees C thermal uniformity (ASTM E3106‑18 §5.1) and ≥12‑log BI inactivation (ISO 11138‑3:2017 §5.4).
除热原隧道与高压灭菌器必须做到严格的验证，满足 FDA 21 CFR 211.113 内毒素去除要求以及欧盟附录 1 10 的负 6 次方无菌保证水平。ICH Q10 的全生命周期方法不可妥协，需要 IQ/OQ/PQ 方案，证明温度均匀性正负 2.5 摄氏度（ASTM E3106‑18 第 5.1 条），生物指示剂实现不低于 12 个对数单位灭活（ISO 11138‑3:2017 第 5.4 条）。

Persistent regulatory asymmetries — particularly PMDA’s annual requalification versus FDA’s risk‑based intervals — impose $1.2 million/year compliance overheads for multinationals. Immediate adoption of ICH Q12 Annex 2 change control protocols, coupled with ASTM E3078‑22 standards for AI‑driven systems, will mitigate these disparities.
持续存在的法规差异，尤其是日本 PMDA 每年再确认对比 FDA 基于风险的周期，给跨国企业带来每年一百二十万美元合规成本。立即落地 ICH Q12 附录 2 变更控制规程，同时采用 ASTM E3078‑22 人工智能系统标准，可以缓解该类差异。

As advanced therapies emerge, harmonization of USP <1229.1> with ISO 17665‑1 Annex B for porous load validation becomes imperative to safeguard patient health while maintaining supply chain integrity.
随着先进疗法产品不断出现，必须推动 USP <1229.1 > 和 ISO 17665‑1 附录 B 多孔装载物验证标准相互协调，在保障供应链完整的同时守护患者安全。